Shares of Opus Genetics (NASDAQ: IRD) surged 32% to $5.73 on Wednesday, following the release of promising early clinical data for its investigational gene therapy OPGx-BEST1, designed to treat BEST1-related retinal diseases. The rally reflects cautious optimism, but the data remain early and the road to approval is still long.
Positive Signals, But Small Sample Size
The company reported that all five patients in the low-dose cohort showed improvement in at least one measure of visual function, with no serious safety concerns. Specifically, best-corrected visual acuity improved in three of five participants, while low-luminance visual acuity and contrast sensitivity each improved in two of five. Retinal sensitivity, as measured by microperimetry, improved in three of four evaluable patients. Structural improvements were also noted, with reduction in vitelliform material in two of three patients with Best vitelliform macular dystrophy and decreased intraretinal fluid in both patients with autosomal recessive bestrophinopathy.
However, this was an open-label, uncontrolled study with only five patients. A patient could meet the improvement criteria through any one of four functional tests, and not all measures improved in every patient. The company itself cautioned in a September 9 SEC filing that these interim results may not predict the final outcome.
FDA Alignment on Pivotal Endpoint
More significant than the stock move may be the company's announcement of a Type C meeting with the U.S. Food and Drug Administration (FDA) held in August. The FDA and Opus agreed on a potential pivotal endpoint: an improvement of at least 3 decibels at five or more prespecified retinal locations on microperimetry, paired with a patient-reported outcome in a randomized, controlled trial. This alignment reduces regulatory uncertainty and provides a clearer path for a registrational study.
While this does not guarantee approval, it does offer a defined target for a disease that currently has no approved therapy targeting its genetic cause.
Next Data Readouts Expected in 2027
Opus has already moved to a higher dose of 4.5 billion vector genomes per eye, three times the low-dose level. The second cohort has been expanded to eight patients, mostly with Best vitelliform macular dystrophy. Dosing is expected to complete in the fourth quarter of 2026, with three-month results anticipated in the second quarter of 2027. Six-month follow-up data for the three low-dose patients with the dominant form of the disease are also due in Q2 2027.
Investors will be looking for consistent microperimetry improvements, durability at six months, a dose-response relationship, and a manageable safety profile at the higher dose. The company also noted that larger functional gains were observed in patients with viable retinal tissue, suggesting that patient selection could enhance the signal, but may also narrow the treatable population.
Financial Position and Cash Runway
Opus reported cash and equivalents of $88.8 million as of June 30. Management says that this cash, combined with potential funding from its Oberland Capital note agreement, can support operations into 2029, excluding warrant proceeds and milestones. However, the company's second-quarter results show increasing R&D expenses of $11.2 million, up from $6.0 million a year earlier, while revenue was just $0.8 million, leading to a net loss of $8.1 million.
The company estimates a larger patient population than previously thought, with 23,600 symptomatic BEST1 patients in the U.S. and 45,400 globally, based on a survey of over 150 eye-care professionals. But these are management-sponsored estimates, and the commercial pool will be reduced by diagnosis rates, eligibility, and treatment capacity.
What Could Drive the Stock Higher?
Wednesday's rally prices in the possibility that OPGx-BEST1 can advance, not proof that it works. The bullish case would strengthen if the higher-dose cohort shows consistent microperimetry responses, the six-month data hold up, and Opus enters a randomized pivotal trial in 2027 without materially shortening its cash runway. Until then, the stock remains a speculative play on early-stage data.
